
Anti-inflammatory Effect of Pentoxifylline

To the Editor:

We read with great interest the recent in vitro study by Tong and colleagues.1 We have some comments. First, the authors implicated the possibility of pentoxifylline as a therapeutic option for pulmonary sarcoidosis. A study2 has described that pentoxifylline has no severe side effects as compared with dexamethasone. However, as Tong et al3 introduced in their discussion, pentoxifylline has no severe side effects as compared with dexamethasone. Fylline has no severe side effects as compared with dexamethasone. Also, dexamethasone suppresses interleukin-1β gene expression in lipopolysaccharide-stimulated RAW 264.7 cells through the inhibition of the activation of transcription factors related to endotoxin such as nuclear factor-κB and activator protein-1.6 Other mechanisms may be present in lipopolysaccharide-induced interleukin-1 production in alveolar macrophages of patients with sarcoidosis.

Ken-ichiro Inoue, MD
Hirohisa Takano, MD, PhD
Rie Yanagisawa, MD
Miho Sakurai, MD
National Institute for Environmental Studies
Tsukuba, Japan

REFERENCES
2 Ward A, Cissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34:50–97
7 Lee SW, Tsou AF, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA. Proc Natl Acad Sci USA 1988; 85:1204–1208

www.chestjournal.org